Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 18,094 as of Thursday, May 28, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 843 issues advancing vs. 2,162 declining with 143 unchanged. The Drugs industry currently is unchanged today versus the S&P 500, which is down 0.4%. Top gainers within the industry include Gilead ( GILD), up 0.7%, and Mylan ( MYL), up 0.7%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 1.2%, Celgene ( CELG), down 1.0%, Sanofi ( SNY), down 0.9% and Biogen ( BIIB), down 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Shire ( SHPG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Shire is up $1.31 (0.5%) to $259.41 on average volume. Thus far, 338,241 shares of Shire exchanged hands as compared to its average daily volume of 618,200 shares. The stock has ranged in price between $257.82-$259.67 after having opened the day at $258.35 as compared to the previous trading day's close of $258.10. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $51.3 billion and is part of the health care sector. Shares are up 20.5% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Shire a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Shire Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.